Latest Observability News

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Stellar Resources reports strong high-grade tin intercepts at Queen Hill, underpinning potential resource upgrades and advancing the Heemskirk Tin Project towards development.

Enlitic has formalised a binding MOU with GE HealthCare to deliver multi-million-dollar migration services, contingent on raising A$10 million through a new capital placement. This partnership and funding round mark a pivotal step in Enlitic’s growth strategy within AI-driven medical imaging.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Patagonia Lithium Ltd reports exceptional Nuclear Magnetic Resonance (NMR) porosity and specific yield results from well JAM24-04 at its Formentera Lithium Brine Project in Argentina, revealing porosity values more than double previous estimates and promising lithium concentrations that bolster project viability.

Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.

Kingsgate Consolidated Limited has announced an on-market share buy-back as part of its capital management strategy, signaling confidence amid current market conditions.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

Peak Minerals has completed a key phase of rutile exploration at its Minta Project in Cameroon, reporting promising heavy mineral findings and appointing a seasoned mining executive as CEO. The company also secured $2 million through a shareholder entitlement offer to fund ongoing activities.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

Cannindah Resources has reported significant diamond drilling results at its Mt Cannindah project, including high-grade gold intercepts and the identification of a large new porphyry copper-gold-molybdenum target, alongside strategic board and management appointments.